Pipeline Overview
G1 is advancing two novel therapies for people living with cancer. Trilaciclib is an investigational therapy designed to reduce chemotherapy-induced myelosuppression for people with cancer. Rintodestrant is a selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer.
The safety and efficacy of investigational agents or an investigational use of an approved product have not been established or approved by the FDA or other regulatory authorities.